Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2403-2413

  Burris III, Howard A ^a   Moore, Malcolm J ^a   Andersen, John ^a   Green, Mark R ^a   Rothenberg, Mace L ^a   Modiano, Manuel R ^a   Cripps, M Christine ^a   Portenoy, Russell K ^a   Storniolo, Anna Maria ^a   Tarassoff, Peter ^a   Nelson, Robert ^a   Dorr, F Andrew ^a   Stephens, C D ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PAIN; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 8244254377     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2403     Document Type: Article

References (41)

1. Warshaw AL, Fernández-del Castillo C: Pancreatic carcinoma. N Engl J Med 326:455-465, 1992
2. Greenwald H, Bonica J, Burgner M: The prevalence of pain in four cancers. Cancer 60:2563-2569, 1987
3. Saltzburg D, Foley KM: Management of pain in pancreatic cancer. Surg Clin North Am 69:629-649, 1989
4. Krech RL, Walsh D: Symptoms of pancreatic cancer. J Pain Symptom Manage 6:360-367, 1991
5. Lebovits A, Lefkowitz M: Pain management of pancreatic carcinoma. A review. Pain 36:1-11, 1989
6. Kelsen DP, Portenoy RK, Thaler HT, et al: Pain and depression in patients with newly diagnosed pancreatic cancer. J Clin Oncol 13:748-755, 1995
7. Brennan MF, Kinsella TJ, Casper ES: Cancer of the pancreas, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 849-882
8. Smalley SR, Macdonald JS: Pancreatic cancer, in Calabres P, Schein PS (eds): Medical Oncology (ed 2). New York, NY, McGraw-Hill, 1993, pp 691-712
9. Kovach JS, Moertel CG, Schutt AJ, et al: A controlled study of combined 1,3-Bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreas cancer. Cancer 33:563-567, 1974
10. Hausen R, Quebbman E, Ritch P, et al: Continuous 5-fluorouracil infusion in carcinoma of the pancreas. Am J Med Sci 295:91-93, 1988
11. Crown J, Casper ES, Botet J, et al: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9:1682-1686, 1991
12. DeCaprio JA, Mayer RJ, Gonin R, et al: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9:2128-2133, 1991
13. Kelsen D, Hudis C, Niedzwiecki D, et al: A phase III comparison trial of streptozotocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965-969, 1991
14. Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65:2207-2212, 1990
15. Moertel CG, Engstrom P, Lavin PT, et al: Chemotherapy of gastric and pancreatic carcinoma: A controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones." Surgery 85:509-513, 1979
16. Frey C, Twomey P, Koehn R, et al: Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 47:27-31, 1981
17. Morrell LM, Ardalan R, Richman SP, et al: A phase II multi-institutional trial of low-dose N-(phosphanacetyl)-L-Aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. Cancer 67:363-366, 1991
18. Crooke ST, Bradnes WT, Mitomycin C: A review. Cancer Treat Rev 3:121-139, 1976
19. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422, 1990
20. Heinemann V, Hertel L, Grindey GB, et al: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-b-D-arabinofuranosyl cytosine. Cancer Res 48:4024-4031, 1988
21. Huang P, Chubb S, Hertel LW, et al: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
22. Ghandi V, Plunkett W: Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675-3680, 1990
23. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
24. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253:2061-2067, 1985
25. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 63:1026-1030, 1989
26. Buroker TR, O'Connell MJ, Wieand HJ, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
27. Anderson JS, Burris HA, Casper E, et al: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 13:461, 1994 (abstr 1600)
28. Fishman B, Pasternak S, Wallenstein SL, et al: The Memorial pain assessment card: A valid instrument for the evaluation of cancer pain. Cancer 60:1151-1158, 1987
29. Brimdage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales; Implications for interpreting toxicity data. J Natl Cancer Inst 85:38-48, 1993
30. Carter SK: The integration of chemotherapy into a combined modality approach for cancer treatment: VI pancreatic adenocarcinoma. Cancer Treat Rev 3:193-214, 1975
31. Tajiri H, Yoshimori M, Okazaki N, et al: Phase II study of continuous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 48:18-21, 1991
32. Mallinson CN, Rake MO, Cocking JB, et al: Chemotherapy in pancreatic cancer: Results of a controlled prospective, randomized, multicentre trial. BMJ 218:1589-1591, 1980
33. Smith FD, Hoth DF, Levin B, et al: 5-fluorouracil, Adriamycin, and mitomycin C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014-2018, 1980
34. Bitran JD, Dresser RK, Kuzloft MF,. et al: Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, Adriamycin and mitomycin C (FAM). Cancer Treat Rev 63:2049-2051, 1979
35. Daugherty J, Kelsen D, Kemens N, et al: Advanced pancreatic cancer: A phase I-II trial of cisplatin, high dose cytarabine and caffeine. J Natl Cancer Inst 81:1735-1738, 1989
36. Wiggans RC, Woolley PV, Macdonald JS, et al: Phase II trial of streptozotocin, mitomycin C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41:387-391, 1978
37. Bukowski RM, Aberhalden RT, Hewlett JS, et al: Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 3:321-324, 1980
38. Jacobs EM, Reeves WJ, Wood DA, et al: Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 27:1302-1305, 1971
39. Rosvold E, Schilder R, Walczak J, et al: Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 29:305-308, 1992
40. Scheithauer W, Pfeffel F, Kornek G, et al: A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2-b-interferon in advanced adenocarcinoma of the pancreas. Cancer 70:1864-1866, 1992
41. Pazdur R, Ajani TJ, Abruzzese JL, et al: Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70:2073-2076, 1992